Calciphylaxis in poems syndrome: A case treated with etidronate

Acta Dermato-Venereologica

Volumn 91, Issue 1, 2011, Pages 98-99

  Yoshikawa, Mika ^a   Uhara, Hisashi ^a   Arakura, Fuyuko ^a   Murata, Hiroshi ^a   Kubo, Hitomi ^a   Takata, Minoru ^a   Yoshida, Kunihiro ^a   Okuyama, R ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ETIDRONIC ACID; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; THALIDOMIDE;

ADULT; ASTHENIA; CASE REPORT; DEBRIDEMENT; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE DURATION; DRUG DOSE REDUCTION; GYNECOMASTIA; HUMAN; HYPERBARIC OXYGEN; HYPERPIGMENTATION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; LEG PARESTHESIA; LETTER; LIVEDO RETICULARIS; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; PARESTHESIA; PHYSICAL EXAMINATION; POEMS SYNDROME; PRIORITY JOURNAL; SKIN BIOPSY; SKIN BRUISING; SKIN CALCIFICATION; SKIN DEFECT; SKIN ULCER; TREATMENT OUTCOME; WOUND CARE; X RAY;

BONE DENSITY CONSERVATION AGENTS; CALCIPHYLAXIS; ETIDRONIC ACID; HUMANS; MALE; MIDDLE AGED; POEMS SYNDROME;

EID: 78751490489     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0968     Document Type: Letter

References (12)

1. Guldbakke KK, Khachemoune A. Calciphylaxis. Int J Dermatol 2007; 46: 231-238.
2. Arseculeratne G, Evans AT, Morley SM. Calciphylaxis - a topical overview. J Eur Acad Dermatol Venereol 2006; 20: 493-502.
3. De Roma I, Filotico R, Cea M, Procaccio P, Perosa F. Calciphylaxis in a patient with POEMS syndrome without renal failure and/or hyperparathyroidism. A case report. Ann Ital Med Int 2004; 19: 283-287.
4. Lesprit P, Authier FJ, Gherardi R, Belec L, Paris D, Melliere D, et al. Acute arterial obliteration: a new feature of the POEMS syndrome? Medicine (Baltimore) 1996; 75: 226-232.
5. Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve 1998; 21: 1390-1397.
6. Dvorak HF. Angiogenesis: update 2005. J Thromb Haemost 2005; 3: 1835-1842.
7. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 1996; 149: 293-305.
8. Mandler RN, Kerrigan DP, Smart J, Kuis W, Villiger P, Lotz M. Castleman's disease in POEMS syndrome with elevated interleukin-6. Cancer 1992; 69: 2697-2703.
9. Gherardi RK, Belec L, Fromont G, Divine M, Malapert D, Gaulard P, et al. Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome. Blood 1994; 83: 2587-2593.
10. Gherardi RK, Chouaib S, Malapert D, Belec L, Intrator L, Degos JD. Early weight loss and high serum tumor necrosis factor-alpha levels in polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes syndrome. Ann Neurol 1994; 35: 501-505.
11. Hanafusa T, Yamaguchi Y, Tani M, Umegaki N, Nishimura Y, Katayama I. Intractable wounds caused by calcific uremic arteriolopathy treated with bisphosphonates. J Am Acad Dermatol 2007; 57: 1021-1025.
12. Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M. Bisphosphonates and atherosclerosis: why? Lupus 2005; 14: 773-779.